Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Theriva Biologics (TOVX)
NYSE MKT:TOVX
Holding TOVX?
Track your performance easily
TOVX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$2.65 - $17.11
Previous Close$3.8
Volume146.34K
Average Volume (3M)615.42K
Market Cap
$5.14M
Enterprise Value-$9.62M
Total Cash (Recent Filing)$16.59M
Total Debt (Recent Filing)$1.83M
Price to Earnings (P/E)―
Beta1.43
Next Earnings
Nov 06, 2024EPS Estimate
-$6.25Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-31.09
Shares Outstanding1,005,249
10 Day Avg. Volume129,232
30 Day Avg. Volume615,420
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
Price to Book (P/B)0.15
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.41
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering1
Theriva Biologics News
PremiumMarket News
3 Penny Stocks to Watch Now, 11/5/24
PremiumCompany Announcements
Theriva Biologics Expands Stock Plans and Share Authority
PremiumCompany Announcements
Theriva Biologics Gains Orphan Drug Status for VCN-01
PremiumCompany Announcements
Theriva Biologics Advances SYN-004 in Clinical Trial
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
TOVX FAQ
What was Theriva Biologics’s price range in the past 12 months?
Theriva Biologics lowest stock price was $2.65 and its highest was $17.11 in the past 12 months.
What is Theriva Biologics’s market cap?
Currently, no data Available
When is Theriva Biologics’s upcoming earnings report date?
Theriva Biologics’s upcoming earnings report date is Nov 06, 2024 which is 4 days ago.
How were Theriva Biologics’s earnings last quarter?
Theriva Biologics released its earnings results on Aug 13, 2024. The company reported -$10.75 earnings per share for the quarter, missing the consensus estimate of -$4.75 by -$6.
Is Theriva Biologics overvalued?
According to Wall Street analysts Theriva Biologics’s price is currently Overvalued.
Does Theriva Biologics pay dividends?
Theriva Biologics does not currently pay dividends.
What is Theriva Biologics’s EPS estimate?
Theriva Biologics’s EPS estimate is -$6.25.
How many shares outstanding does Theriva Biologics have?
Theriva Biologics has 1,353,862 shares outstanding.
What happened to Theriva Biologics’s price movement after its last earnings report?
Theriva Biologics reported an EPS of -$10.75 in its last earnings report, missing expectations of -$4.75. Following the earnings report the stock price went down -0.386%.
Which hedge fund is a major shareholder of Theriva Biologics?
Among the largest hedge funds holding Theriva Biologics’s share is Fisher Asset Management LLC. It holds Theriva Biologics’s shares valued at N/A.
---
Theriva Biologics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Hedge Fund Trend
Decreased
By 502.0 Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.9%
Last 30 Days ▲ 11.1%
Last 30 Days ▲ 11.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-70.63%
12-Months-Change
Fundamentals
Return on Equity
-59.07%
Trailing 12-Months
Asset Growth
-35.23%
Trailing 12-Months
Company Description
Theriva Biologics
Synthetic Biologics, Inc. is a clinical stage company, which engages in the development of therapeutics to preserve the microbiome to protect and restore the health of patients. Its product portfolio includes SYN-010 and SYN-004. The SYN-010, which is intended to reduce the impact of methane-producing organisms in the gut microbiome to treat an underlying cause of irritable bowel syndrome with constipation. The SYN-004, which is designed to protect the gut microbiome from the effects of certain commonly used intravenous (IV) antibiotics for the prevention of C. difficile infection, antibiotic-associated diarrhea, and the emergence of antimicrobial resistance. The company was founded by Steven H. Kanzer in January 2001 and is headquartered in Rockville, MD.
---
TOVX Earnings Call
Q4 2024
0:00 / 0:00
---
TOVX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering TOVX
1 Year
1 Year Success Rate
0/10 ratings generated profit
1 Year Average Return
-49.16%
reiterated a buy rating 3 months ago
Copying Jason McCarthy's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -49.16% per trade.
---